| Literature DB >> 34899870 |
Bingbo Zhou1, Chuan Zhang1, Lei Zheng1, Zhiqiang Wang2, Xue Chen1, Xuan Feng1, Qinghua Zhang1, Shengju Hao1, Liwan Wei3, Weiyue Gu3, Ling Hui1.
Abstract
Introduction: Neurodevelopmental disorders with language impairment and behavioral abnormalities (NEDLIB) are a disease caused by heterozygous variants in the glutamate ionotropic receptor AMPA type subunit 2 (GRIA2) gene, which manifest as impaired mental development or developmental delay, behavioral abnormalities including autistic characteristics, and language disorders. Currently, only a few mutations in the GRIA2 gene have been discovered.Entities:
Keywords: GRIA2 gene; behavioral abnormalities; case report; language impairment; neurodevelopmental disorder
Year: 2021 PMID: 34899870 PMCID: PMC8655903 DOI: 10.3389/fgene.2021.794766
Source DB: PubMed Journal: Front Genet ISSN: 1664-8021 Impact factor: 4.599
FIGURE 1Novel heterozygous de novo GRIA2 mutation causes NEDLIB. Pedigree and Sanger sequencing validation for the GRIA2 NM_001083619.1: c.1934T > G (p.Leu645Arg) variant in an affected individual compared with healthy parents.
FIGURE 2Pattern diagram of the GRIA2 gene structure, protein domain, protein function, and transmembrane domain and protein sequence conserved analysis. (A) GRIA2 gene (NM_001083619.1) contains 16 exons, and exons 2–15 are involved in gene coding. (B) Pattern diagram of the GRIA2 protein domain. It shows the currently reported missense mutation sites that cause NEDLIB and the sites in this study (red font). GRIA2 protein mainly has the following three domains: ANF_recepter (green), Lig_chan-Glu_bd (red), and Lig_chan (blue). The three transmembrane structure regions (orange diamond) are all concentrated on Lig_chan. (C) ANF_recepter and LIG_chan-glu_BD are located outside the cell membrane. Lig_chan had three transmembrane regions. L645R mutation site (red arrow) is in the second transmembrane region. (D) Multiple sequence alignment of GRIA2 proteins from 7 species shows that the L645R mutation site is within the conserved sequence. Human (Homo sapiens, NP_001077088.2), Norway rat (Rattus norvegicus, NP_001077280.1), chimpanzee (Pan troglodytes, NP_001171923.2), house mouse (Mus musculus, NP_001077275.2), cattle (Bos taurus, NP_001069789.2), chicken (Gallus gallus, NP_001001775.2), and tropical clawed frog (Xenopus tropicalis, NP_001135539.1).
FIGURE 33D image of GRIA2 protein. (A) is the 3D overall picture of wild-type (WT) GRIA2 protein (645Leu is in the red frame). (B) is the 3D partial enlarged view of wild-type GRIA2 protein. 645Leu (WT) and 641Leu form a hydrogen bond. (C) is the 3D overall picture of mutant (MUT) GRIA2 protein. (D) is the 3D partial enlarged view of mutant GRIA2 protein. 645Arg (MUT) and 641Leu form two hydrogen bonds.
Clinical phenotypes of patients with missense variation of the GRIA2 gene reported to date.
| Patient | Variant | Age | Gender | DD | ID | ASD | Speech impairment | Abnormal behavior | Seizures | Brain imaging | Study |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | c.140G > A; p.Gly47Glu | 13 years | F | Yes | Yes | Yes | Yes | Yes | No | N/A |
|
| 2 | c.345C > G; p.Ser115Arg | N/A | N/A | N/A | N/A | Yes | N/A | N/A | N/A | N/A |
|
| 3 | c.905A > G; p.Asp302Gly | 10 years | M | Yes | Yes | Yes | Yes | No | No | Normal |
|
| 4 | c.1582C > A; p.Pro528Thr | 9 years | M | Yes | Yes | Yes | Yes | Yes | No | Normal |
|
| 5 | c.1819C > G; p.Arg607Gly | 11 years | F | Yes | Yes | Yes | Yes | Yes | Yes | Abnormal |
|
| 6 | c.1825G > A; p.Gly609Arg | 19 years | F | Yes | Yes | No | Yes | Yes | No | Yes |
|
| 7 | c.1831G > A; p.Asp611Asn | 19 years | M | Yes | Yes | Yes | Yes | Yes | No | Normal |
|
| 8 | c.1915G > T; p.Ala639Ser | 3 ms | M | Yes | N/A | N/A | N/A | N/A | Yes | Abnormal |
|
| 9 | c.1915G > T; p.Ala639Ser | 5 ms | F | Yes | N/A | N/A | N/A | N/A | Yes | Abnormal |
|
| 10 | c.1932C > A; p.Phe644Leu | 8 years | F | Yes | Yes | Yes | Yes | Yes | No | Normal |
|
| 11 | c.1934T > G; p.Lys645Arg | 3 years | F | Yes | N/A | No | Yes | Yes | No | Abnormal | Current study |
| 12 | c.1937C > A; p.Thr646Asn | 3 years | F | Yes | N/A | No | Yes | No | Yes | Abnormal |
|
| 13 | c.1939G > C; p.Val647Leu | 9 years | M | Yes | Yes | N/A | Yes | No | Yes | Abnormal |
|
| 14 | c.1939G > C; p.Val647Leu | 5 years | M | Yes | Yes | Yes | Yes | No | Yes | Abnormal |
|
| 15 | c.1939G > C; p.Val647Leu | 3 years | M | Yes | Yes | N/A | Yes | No | Yes | Normal |
|
| 16 | c.1939G > C; p.Val647Leu | 5 years | M | Yes | Yes | N/A | Yes | No | Yes | Abnormal |
|
| 17 | c.2363G > T; p.Trp788Leu | 3.5 years | M | Yes | Yes | N/A | Yes | No | Yes | Abnormal |
|
| 18 | c.2375G > T; p.Gly792Val | 31 years | F | Yes | Yes | Yes | Yes | Yes | No | N/A |
|
| 19 | c.2420C > T; p.Ala807Val | 3.6 years | F | Yes | Yes | Yes | Yes | Yes | Yes | Normal |
|
| 20 | c.2435A > G; p.Asn812Ser | 3 years | M | Yes | Yes | Yes | Yes | Yes | No | Normal |
|
DD, developmental delay; ID, intellectual disability; ASD, autism spectrum disorder; ys, years; ms, months.